Producing EVs at the Clinical Scale On November 11, we presented at the Exosome Based Therapeutic Development Digital Summit. At this key exosome industry event, we had the opportunity to highlight our LEAP technology, the team’s accomplishments and our commitment to collaboration to advance the development of all exosome therapeutics. Our Chief Commercial Officer, Dr […]
“The biggest problem is to purify the EVs from their source and to eliminate the contaminants, and not damage the EVs,” says Managing Director and founder Dr Ian Dixon. One of the great things about our LEAP technology and process is that it is scalable. You can read the full Stockhead article here.
Chief Commercial Officer, Dr Chris Baldwin, will present to the Exosome Based Therapeutic Development Digital Summit on 11 November (9:00 AM US Eastern Time, 1.00 AM AEDT), the first day of the two-day event. You can find the slide deck here.
Our science is too important to leave to just the scientists. On November 5, Dr Balarka Banerjee and Dr Kartini Asari explained some of the advances Exopharm is making. This science update forms part of our ‘Behind the Scenes’ webinar series. Stem Cells: Exosome Factories Dr. Balarka Banerjee, Cell Development Manager Exopharm’s unique LEAP […]
“With a successful outcome from PLEXOVAL II, Exopharm will be well-positioned to initiate Phase 2 studies with off-the-shelf Plexaris and Phase 1 studies with our mesenchymal stem cell EV product Cevaris,” said Angus Tester, Head of Product Evaluation. You can read the full Stockhead article here.
Yesterday, Chief Commercial Officer Chris Baldwin sat down with Stockhead’s resident health and biotech expert Tim Boreham for the latest episode of The Health Kick Podcast. They discuss the potential of exosomes to transform healthcare, and our journey to commercialising our exosome therapeutics. Click below to listen. You can find the full post here.
How mRNA vaccines could defeat the novel coronavirus Head of Innovation Andy Coley spoke with Stockhead about the potential of mRNA for fighting COVID-19, including Moderna’s vaccine candidate and Fortrexo, our engineered EV approach. You can find the full article here.
ShareCafe’s “Hidden Gems” Webinar 18 Sept 2020 Chief Commercial Officer Chris Baldwin provides updates on Exopharm’s Technology and Naive EV programs, including the addition of Alison Mew to the senior leadership and the progress on Exopharm’s second clinical trial.
Behind the Scenes with our Scientists Recently, there has been a variety of updates about the company’s business progress and accomplishments. This webinar provided a closer look at some of science and technology behind our most recent advances, Fortrexo CoV™ and Exoria™. RNAi’s to Stop Coronavirus Dr Karen Holden, Head of Translation Exopharm has […]
Exopharm has announced a placement of shares to raise $10 million. Canary Capital, the manager of the placement, and its directors have elected to take the majority of their fees in shares. “In Exopharm, Canary has identified an Australian company with proprietary technology that can compete on the world stage”, says Paul Hart, Executive Director […]
“As a serial biotechnology entrepreneur, Dr Dixon doesn’t just develop technologies or products – he wants to build long-lasting businesses based upon big ideas.” Written by our Chief Commercial Officer Chris Baldwin, this Sharecafe article explains Dr Dixon’s big idea back in 2013 and how it led to the foundation of Exopharm. Today, Exopharm is […]
Exopharm CCO Dr Chris Baldwin gives a shareholder update on the ‘Morning Twilight Briefing’ webinar series hosted by Monsoon Communications. Chris discusses Exopharm’s key development areas and provides an overview of the company’s engineered EV technology.
Biotech Daily’s Tim Boreham likes Exopharm’s focus: “Given the scientifically complex nature of Exopharm’s quest to develop exosomes into therapeutics, it’s good to see that founder and chief executive Ian Dixon hasn’t lost sight of the commercial basics.” Read the full article here.
MST Access, a division of MST Financial which provides institutional-grade research for small and medium cap companies, has initiated coverage of Exopharm Ltd (ASX: EX1). Read the full report here.
Their Curiosity and Enthusiasm are Infectious… Recently Chief Commercial Officer Chris Baldwin sat down with StockPal to discuss the CEO mindset. Read Chris’ thoughts on Exopharm, measuring success, and the future of exosome medicines. Read the full article on Stockpal Asia.
BD Team Welcomes Partners The Business Development team is excited to be participating in the virtual “Bio Digital Partnering Convention 2020.” With over 30 meetings with potential business partners from around the globe already planned, they are eager to find partners to help us in our mission to bring exosome medicines to the world. Other […]
Exopharm Webinar May 2020 – Our Strategic Response to COVID-19 Exopharm updates the public on its recent progress and activities. Hosted by Jason Watson, Chair of Exopharm, Ian Dixon (CEO), Gregor Lichtfuss (COO) and Chris Baldwin (CCO) discuss how COVID-19 has affected operations and strategies. The application of Exopharm’s engineered exosome program, Fortrexo, is discussed, […]
Exopharm: Preparation, Demonstration and Reward As a biotech stock, order or to maximise the financial returns from our technologies and products there are a number of aspects to the business of Exopharm. As a headline, we see ourselves as world leaders in a new type of regenerative medicine – harnessing exosomes as the ‘secret sauce’ […]